Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA COVID-19 Adcom: What Additional Members Are Needed?

Executive Summary

Beyond vaccine experts, specialists in medical areas where there might be safety concerns, as well as epidemiologists, could be helpful to aid the FDA in understanding the data in a coronavirus vaccine application. 

You may also be interested in...



US FDA ‘Flexible’ With Vaccine Safety Data Requirements, CBER’s Peter Marks Says

The median of two months of follow-up is not absolute, but agency flexibility is limited.

Convalescent Plasma EUA Will Not Complicate Hyperimmune Globulin Product Development, Sponsors Say

US FDA authorization will further boost already-high demand for plasma from individuals recovered from COVID-19 and increase competition for donors, NYU’s Arthur Caplan predicts, but CoVIg-19 Plasma Alliance and Emergent BioSolutions say they do not expect EUA to impact either product supply or enrollment in upcoming randomized trials of their H-Ig products.

US FDA's Hahn Promotes Provider Role In Boosting Public Confidence In COVID-19 Products

Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS142737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel